An Integrated Radio-immunological Approach

The most aggressive primary brain tumors in adults, glioblastomas, are characterized by a profound local and systemic immune suppression. During tumor progression, the infiltration of inflammatory leukocytes, especially of myeloid origin, endowed with immunosuppressive function is observed. Aim of this study is to evaluate myeloid cell infiltrate and iron metabolism in tumor-associated macrophages by combining a multimodal MRI imaging technique with immunophenotyping of the tumor microenvironment.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Glioma, Malignant Glioma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital, Florence, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients with histologic confirmation of malignant glioma
Patients must be age >= 18 years
Patients must be able to obtain an MRI scan with gadolinium contrast
Patients must sign informed consent indicating that they are aware of the investigational nature of this study:

Treatment and study plan

Primary outcomes

Evaluate leukocyte/myeloid cell-infiltrate in gliomas by using a multimodal PET/MRI imaging technique

Time frame: 24 months

apply iron-sensitive MRI sequences in glioma patients to identify macrophage iron deposits as biomarker of in vivo immune suppression, and correlate these findings with 5-Ala intraoperative data and analysis of MG and BMDM infiltration.

Sponsors and collaborators

Lead sponsor

Istituto Oncologico Veneto IRCCS

Other

Collaborators

Azienda Ospedaliera di Padova
Azienda Ospedaliero-Universitaria Careggi

Registry information

Official study title

Identification of the Immuno Suppressive Characteristics of Glioma Patients by an Integrated Radio-immunological Approach

Acronym: IMMUNO-IMAGING

Important dates

Study start: 2022
Primary completion: 2025
Study completion: 2026
First posted: Mar 4, 2022
Registry last updated: Jan 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting